

BETTER. FASTER. STRONGER.



Better Therapies

Faster Diagnosis

Stronger Hearts

UHN Research Snapshot

TOTAL RESEARCHERS 1,094
Appointed Researchers 464
Clinical Researchers 630

RESEARCH SPACE 969,913 sq. ft.

TOTAL FUNDING \$386,192,252

TOTAL TRAINEES 783
Fellows 309
Graduate Students 474

TOTAL STAFF 2,098
Institute Staff 1,802
Research Support Staff 296

PUBLICATIONS 3,732

The cover features six UHN researchers whose work exemplifies how we are making health care better, faster and stronger. They are, from top left (clockwise): Drs. Karen Davis, Thomas Purdie, Pamela Ohashi, Michael Laflamme, Frank Rudzicz and Cristina Nostro.

University Health Network (UHN) is a research hospital affiliated with the University of Toronto and a member of the Toronto Academic Health Science Network (TAHSN). UHN comprises the Michener Institute for Education at UHN and four hospitals: the Princess Margaret Cancer Centre (PM Cancer Centre), Toronto General Hospital (TGH), Toronto Rehab (TR) and Toronto Western Hospital (TWH). It has five research institutes: Krembil Research Institute (Krembil), PM Cancer Centre, Techna Institute for the Advancement of Technology for Health (Techna), Toronto General Hospital Research Institute (TGHRI) and Toronto Rehabilitation Institute (TRI). The scope of research and complexity of cases at UHN have made it a national and international source for discovery, education and patient care.

BETTER. FASTER. STRONGER.

Welcome Message: Pushing the Limits	2
Featured Research	
Why Some Gain When Under Pain More flexible communication in the brain could make pain less of a distraction while performing a task	4
Making Every Move Count Research exposes a hidden defence mechanism that protects cancer from the body's immune system	6
Reading Between the Lines New artificial intelligence platform can diagnose and monitor Alzheimer disease using verbal descriptions of an image	8
On Target for Cell Therapy New method could lead to safer stem cell-derived diabetes treatments	10
Artificial Intelligence Feeds Need for Speed Technology is being used to fast-track radiation therapy plans and conserve clinical resources	12
From Building Blocks to BlueRock BlueRock Therapeutics receives historic investment to advance stem cell research	14
Support: New funding spurs world-class innovation	16
Discovery: A selection of top research findings	18
Impact: How research at UHN is improving health care	20
UHN Foundations	22
Research Distinctions Research Institutes Research Committees External Sponsors Financials Research Trustee and Advisory Boards	26 28 40 43 47 48

Welcome Message

Pushing the Limits

High-performance athletes train for years to become the best in their field. They consistently push themselves beyond what they are capable of, honing their skills through an unwavering drive. And once they've attained their goal—be it breaking a personal best, winning a gold medal or shattering a world record—it's on to the next challenge.

The same can be said of our researchers.

Our researchers tirelessly work to better understand disease, improve the delivery of care, and the effectiveness and efficiency of the health care system. Along with clinicians, health care professionals, funders and patients, they make a united front to define the most important unmet needs. And together they work to address these needs while setting and achieving goals that are far beyond what would be possible as individuals.

Some of our researchers set their sights on creating a better understanding of disease as a path towards improved health. Examples include those who reveal new molecular targets that lead to the development of better, more specific therapeutic drugs; those who identify gaps in care that inform new, more effective clinical tools and policies; and those who find better ways to bring basic research findings to the clinic to help patients. This knowledge can be translated into a better approach to doing something, whether it's a research method, therapeutic strategy or way of performing surgery. These solutions continually enhance and refine the delivery of health care.

Emerging technologies have enabled other researchers to improve care at an increasingly faster pace. These technologies include advanced DNA sequencing approaches that reveal the complexities of the human genome with unprecedented speed. Our researchers are also developing machine learning methods to reduce the time it takes to plan treatments, so that patients get the care they need sooner. Both examples demonstrate how our researchers are using these technologies to their fullest potential to accelerate the application of research, the delivery of quality care and to ease the burden on the health care system by reducing wait times.

Others still are building stronger systems. Our researchers are experts in regenerative approaches to repair damaged organs, and leaders in developing rehabilitation programs to strengthen patients' minds and bodies as they age or recover from life-threatening situations. Some are translating their work by commercializing new products or founding new companies through history-making investments from private sector partners; these deliverables fortify the bioeconomy and reinforce the profile of Toronto's research ecosystem on the world stage. Regardless of the means, those engaged in these activities strive to build robust systems-from cells, tissues and organs to networks, consortia and companies – towards enriching human health and wellbeing.

We hope you will enjoy the examples we selected in this year's report to highlight how our researchers are helping to make health care better, faster and stronger.



Programs, Quality and Safety; Chief Medical Officer.

Why Some Gain When Under Pain

More flexible communication in the brain could make pain less of a distraction while performing a task

Despite being hampered by painful injuries, many athletes continue to compete and win. For example, Toronto Maple Leafs defenceman Bobby Baun played several playoff games with a broken ankle and helped his team win the Stanley Cup in 1964.

Why is it that some individuals can perform a task—and do it well—while experiencing pain?

"There is a complex relationship between pain and attention, where pain can modulate attention and vice versa. Moreover, the interplay between these two factors differs from one person to the next," explains Dr. Karen Davis.

Dr. Davis has shown that individuals can be classified as one of two types depending on how pain affects their performance in doing a task. In P-type individuals, pain impedes their ability to perform a task; whereas, in A-type individuals, like Bobby Baun, pain enhances their performance.

To gain a better understanding of the brain mechanisms that contribute to this divergent behaviour during pain, Dr. Davis and her PhD student Joshua Cheng led a study examining patterns of brain activity in these two groups.

First, 51 healthy participants were classified as either A-type or P-type based on their performance in a complex mental task in the presence and absence of a painful stimulus. Next, the participants underwent a functional MRI (fMRI) scan, while they were not thinking of anything in particular, to measure their spontaneous brain activity.

The researchers focused their study on the activity of brain cells in two networks: the executive control (EC) network and the salience network. The EC network helps to optimize a person's behaviour in response to what's happening around them; whereas, the salience network is normally engaged when something like pain draws your attention.

Through their analysis, Dr. Davis and her research team discovered a link between spontaneous brain activity and task performance with pain. The synchrony of activity between the EC network and the salience network, as well as within the salience network, was more flexible in A-type individuals than P-type individuals. These findings suggest that brain communication is more flexible in A-type individuals—a feature that could be important for prioritizing task performance over pain, producing better performance.

Regarding her future work, Dr. Davis says, "We'd like to explore whether communication flexibility is disrupted in chronic pain and how it is altered by treatments for chronic pain—including surgery, medications and cognitive-behavioural therapy. This will improve our understanding of the mechanisms underpinning chronic pain, which will be instrumental for developing more effective and personalized therapies for this debilitating condition."

Cheng JC et al. Neuroimage. 2017 Aug 15;157:61-68. Supported by the Canadian Institutes of Health Research and the Toronto General & Western Hospital Foundation. "When I play hockey, my mind is so focused on the game and scoring a goal that I don't feel my recurring back and knee pain," confides Dr. Davis, an avid hockey player and Leafs fan.





and attention is illustrated by two hockey players facing off.

Making Every Move Count

Research exposes a hidden defence mechanism that protects cancer from the body's immune system

The best defence is a good offence. This adage, often applied to sports or military strategies, suggests that attacking one's opponent offers the greatest protection. Researchers and clinicians are taking this approach to fight cancer—developing powerful new therapies that seek out and kill cancer cells.

One such approach is immune therapy: it works by boosting the number and activity of tumour-infiltrating lymphocytes (TILs), immune cells that go on the offensive by migrating into tumours to target and destroy them. Although this strategy holds promise, challenges remain because certain tumours have developed defence mechanisms that block TIL activity.

These tumours, however, are no match for Dr. **Pamela Ohashi**. She is a pioneer in figuring out how the immune system interacts with cancer in order to develop new immune therapies.

In an article published in the prestigious journal *Nature Medicine*, Dr. Ohashi and her research team revealed that an internal battle may be going on: they found that certain ovarian tumours contain other immune cells, called regulatory innate lymphoid cells (ILCregs), that block the activity of cancer-fighting TILs. The ILCregs did this in two ways: they reduced the ability of TILs to grow and multiply, and altered the ability of the TILs to attack cancer cells.

The team also found that the tumours from some patients contained ILCregs, while those from others did not, suggesting that some tumours may be able to attract or promote growth of ILCregs.

"By looking at tumour biology from this different perspective, we have a better understanding of the barriers that prevent a strong immune response," explains Dr. Ohashi. "Our research reveals a promising new strategy to develop combined therapies that simultaneously target ILCregs while promoting TIL growth and function—delivering a stronger 'one-two punch' against the disease."

Building on these findings, her team is now developing a test to identify ILCregs in patients, which may help predict whether the patient will respond to immune therapy. Dr. Ohashi says, "This knowledge would help doctors and patients make more informed medical decisions, personalize cancer treatment and ultimately improve the effectiveness of immune therapies."

Immune therapies work by helping the immune system to target and kill cancer.

Crome SQ, et al. Nat Med. 2017 Mar;23(3):368-375. Supported by the Canadian Institutes of Health Research, the Cancer Research Institute/Irvington Institute, the Canada Foundation for Innovation, the Ontario Ministry of Research, Innovation and Science, the Alexander von Humboldt Foundation, the German Research Council, the National Institutes of Health, the Parker Institute for Cancer Immunotherapy and The Princess Margaret Cancer Foundation. P Ohashi is a Tier 1 Canada Research Chair in Autoimmunity and Tumour Immunity.

Image: (opposite page) just as a chess player uses offensive and defensive strategies to win, Dr. Ohashi is finding ways to weaken cancer's defences while boosting the body's immune system.



Reading Between the Lines

New artificial intelligence platform can diagnose and monitor Alzheimer disease using verbal descriptions of an image

How you speak says a lot about you. A hurried voice can show that you are in a rush, while the tone of your voice can reveal emotion and mood.

How you speak can also uncover deeper truths: it can provide insight into your mental health. For example, speech can be used to diagnose aphasia, a disorder caused by brain damage that compromises an individual's ability to speak, write or understand language.

"While speech analysis represents a powerful approach to diagnose certain disorders, this method typically relies on tedious 'paper-and-pencil' tests that are time consuming and costly to administer and interpret," says Dr. Frank Rudzicz.

To address the shortcomings of traditional speech-based tests, Dr. Rudzicz's team has combined subtle differences in speech patterns with the power of artificial intelligence (AI) to create a clinical tool that can quickly diagnose Alzheimer disease.

Alzheimer disease progressively damages the brain, impairing memory. Although memory loss is the most definitive symptom, speech may be a more sensitive indicator of brain function: not only do speech deficits appear early in the disease, but they also worsen as it progresses.

As a first step toward developing the new clinical tool, the research team identified the most prevalent speech deficits in Alzheimer disease. They did this by analyzing brief speech samples from 264 participants (167 with Alzheimer disease and 97 without).

For each audio sample, 370 features of speech were examined, such as vocabulary richness, vowel articulation and pauses between words. Next, the researchers used this data to teach an AI algorithm how to identify Alzheimer disease. The resulting speech-based diagnostic program was able to detect the disease with an accuracy of more than 80%. Not only is the new program just as accurate as traditional assessment methods, but it is faster, cheaper and more sensitive.

Dr. Rudzicz incorporated these findings into a set of assessment tools that can detect a variety of disorders including aphasia and types of dementia. This platform can also be used to monitor disease progression and the effectiveness of new treatments.

To bring this technology to market, Dr. Rudzicz co-founded the spin-off company WinterLight Labs. The result: an online app that is accessible and easy to use. From the comfort of their own home, patients can upload a short voice recording describing what they see in an image—such as a picture taken during a camping trip. Within seconds, the speech sample is analyzed to generate a set of scores describing speech deficits and mental function, which are then interpreted by clinicians.


WinterLight's app offers a healthier future: one day your phone may be able to notify you at the earliest sign of disease so that preventative therapies could be started to help you stay healthy and active.

Fraser KC, et al. J Alzheimers Dis. 2016;49(2):407-22. Supported by the Natural Sciences and Engineering Research Council of Canada, the Alzheimer's Association, the Alzheimer Society of Canada, the National Institutes of Health and Toronto Rehab Foundation.






"WinterLight's platform could help doctors make accurate diagnoses faster."



and and they had left se



Images: (panel on left) Dr. Frank Rudzicz; (on this page) within seconds, the WinterLight platform can analyze over 400 features in recorded speech samples to assess a person's mental function.

To learn more, please visit the WinterLight Labs website:
http://www.winterlightlabs.com/

On Target for Cell Therapy

New method could lead to safer stem cell-derived diabetes treatments

Looking at things from a different angle can often lead to new and better solutions. That's because a fresh perspective can help to inspire creativity, innovative thinking and collaboration.

It's also why Dr. Cristina Nostro and her team recently embarked on a new collaborative project to solve a particularly difficult research problem: how to reliably isolate a specific pancreatic cell type capable of improving current treatments for type I diabetes.

Type I diabetes is a chronic condition in which cells in the pancreas—known as beta cells—are destroyed so little to no insulin is produced. Without insulin, the body is unable to keep blood sugar levels within a healthy range. When blood sugar levels remain consistently high for a prolonged period of time, serious conditions can develop, including heart disease, vision loss, kidney disease and nerve damage.

Transplanting healthy beta cells into the pancreas can restore insulin production and decrease the number of insulin injections needed to maintain normal sugar levels. However, widespread use of this treatment is hampered by a limited supply of donor beta cells for transplantation.

Using stem cells, Dr. Nostro has addressed this issue by developing a reproducible method for generating large numbers of cells that can safely give rise to insulin-producing beta cells. The technique, which mimics what occurs during pancreas development, forces stem cells to mature into

daughter stem cells (pancreatic progenitors) that then develop into insulin-producing beta cells.

Unfortunately, the technique also produces progenitors that mature into cells that do not produce insulin. The problem: these contaminating progenitors need to be removed before the therapeutic insulin-producing cells can be safely used in the clinic.


Dr. Nostro teamed up with Dr. Thomas Kislinger to explore an entirely new approach to solving this problem. Together they identified specific proteins that are found on the surface of the pancreatic progenitors. They then used one of the proteins—known as Glycoprotein 2—to isolate the pancreatic progenitors and remove the contaminating cells. This allowed them to not only control the number but also the purity of the newly generated insulin-producing cells.

"Our long-term goal is to cure type I diabetes using transplants of insulin-producing cells, so it is crucial to have cells that are safe and pure," explains Dr. Nostro. "The technique we've developed provides a better, more reliable method for generating large quantities of these cells for use in the clinic."

Cogger KF, et al. Nat Comm. 2017 Aug 24;8(1):331. Supported by the McEwen Centre for Regenerative Medicine and the Toronto General & Western Hospital Foundation, the Banting and Best Diabetes Centre, the Canadian Institutes of Health Research, the Ontario Ministry of Health and Long-Term Care, the National Institutes of Health, the Juvenile Diabetes Research Foundation, the US Department of Veterans Affairs and the Vanderbilt Diabetes Research and Training Center.



"This new approach will help us to develop safer stem cell therapies for diabetes."



In their quest to improve stem cell-derived diabetes treatments, Dr. Nostro (pictured) and her team developed an approach to reliably target and isolate insulin-producing beta cells (depicted as fluorescently labelled green and blue cells).



Artificial Intelligence Feeds Need for Speed

Technology is being used to fast-track radiation therapy plans and conserve clinical resources

Radiation therapy is simple in its concept: highenergy radiation can damage and destroy cells, so beams of radiation are directed at a tumour to kill cancer cells. However, the treatment must also carefully minimize the dose to nearby organs.

Actually creating a plan that balances these conflicting requirements can be incredibly complex—it requires dedicated time from a team of highly trained experts. Each patient's anatomy and tumour shape are unique, and it takes a lot of clinical resources and expertise to create a high-quality plan.

That may not be the case for much longer. Dr. Thomas Purdie and his team, including Dr. Chris McIntosh, have used the power of artificial intelligence (AI) to develop a new system that can create a high-quality plan in minutes—

faster than current approaches, which can take days. The technology, known as AutoPlanning, uses machine learning to harvest information from a massive database of proven radiation therapy plans from Princess Margaret Cancer Centre.

While no two patients are identical, there can be similarities. The AutoPlanning AI can evaluate many features in a patient's images, and find other patients in the database with similar features. Then, it builds a radiation therapy plan for the new patient based on information in the plans of patients with similar features.


With thousands of high-quality plans to learn from, the system rapidly adapts and optimizes the plan to suit the new patient.



"The technology allows radiation medicine teams to take on more complex cases and provide precision medicine to more patients," says Dr. Purdie.

Earlier this year, UHN announced that AutoPlanning has been licensed to RaySearch Laboratories of Sweden with the help of UHN's Technology Development and Commercialization Office. The deep learning algorithms of the AutoPlanning system will be integrated into RaySearch's RayStation treatment planning system next year. Johan Löf, CEO of RaySearch, says, "This technology has the potential to make a huge contribution to patient care. I am delighted to be able to bring its benefits to centers around the world as part of the RayStation platform."

Images: (above) Dr. Thomas Purdie; (opposite page) radiation therapy requires precise targeting and planning to account for a patient's unique anatomy and tumour shape.



From Building Blocks to BlueRock

BlueRock Therapeutics receives historic investment to advance stem cell research

Toronto's stem cell and regenerative medicine ecosystem gained a major player with the establishment of a new biotechnology company, BlueRock Therapeutics, in December 2016. The company, co-founded by world-renowned UHN researchers, Drs. Gordon Keller and Michael Laflamme, will advance novel stem cell-based treatments for a variety of diseases, such as cardiovascular disease and Parkinson disease, in a state-of-the-art 10,000 square foot facility.

One of the first innovations that will be developed by the company is an approach to regenerate and repair damaged heart muscles, co-created by the two UHN researchers. Drs. Keller and Laflamme developed a way to coax stem cells into becoming specialized heart muscle cells called cardiomyocytes. These cells, when introduced into the heart, act like building blocks—incorporating into the heart tissue and making the heart stronger by repairing muscle damage caused by heart attacks or abnormal heart rhythms.

"We've had a lot of research breakthroughs in the past several years and with BlueRock we can now move them from the laboratory to the clinic to help patients," said Dr. Laflamme during the launch event, which was attended by federal and provincial ministers and the Premier of Ontario.

BlueRock was made possible by Bayer AG and Versant Ventures, who provided US\$225 million in seed funding. The funds, which represent one of the largest biotechnology investments in history, will be used to build and support research and

development facilities in Toronto, New York and Boston. The Toronto facility will employ up to 70 scientists and technical staff when fully functional.

Sparked by the discovery of stem cells at UHN more than 50 years ago, the local stem cell research community is home to leading centres such as UHN's McEwen Centre for Regenerative Medicine and the Centre for Commercialization of Regenerative Medicine. BlueRock now joins this vibrant cluster of excellence in regenerative medicine, reinforcing Toronto's world-class reputation in the field.

BlueRock builds upon Toronto's excellence in stem cell research.

"The concentration of stem cell research resources and expertise that we have is unparalleled," says Dr. Keller, who is also the Director of the McEwen Centre. "Establishing BlueRock Therapeutics is a visionary move that will lead to new therapies for currently untreatable diseases."

UHN's Technology Development and Commercialization Office worked closely with all partners to negotiate and execute the license agreements for the foundational intellectual property, as well a master research agreement to fund future work.

Image: (L-R) Dr. Gordon Keller and Dr. Michael Laflamme.







Support

New funding spurs world-class innovation



Federal Support for Basic Research

UHN was the top-funded research hospital in the Canadian Institutes of Health Research's 2016–2017 Foundation and Project Grant Program competitions.

For the Foundation Grant Program competition, UHN recieved a total of \$22.9 million in funding for eight awards—representing the second highest number of awards given to a single institution and a success rate almost double the national average.

These projects were led by Dr. Cheryl Arrowsmith (gene packaging in cancer), Dr. Robert Chen (brain connections in movement disorders), Dr. Myron Cybulsky (immune cells in blood vessel disease), Dr. John Dick (leukemia stem cells), Dr. Mitsu Ikura (the role of calcium in cancer growth), Dr. Rama Khokha (genetic and environmental factors driving cancer), Dr. Aaron Schimmer (therapeutic strategies for leukemia) and Dr. Gang Zheng (nanotechnology for anti-cancer drug delivery).

Similarly, UHN fared well above the national average in the Project Grant Program competition, with 22 projects receiving a total of \$17.9 million.



Funding Proactive Research

A team of researchers led by Dr. Rosemary
Martino received US\$8.5 million from the Patient-Centered Outcomes Research Institute. The funding will support a multi-site study, called PRO-ACTIVE, that will focus on evaluating the effectiveness of proactively providing therapy to help those with head and neck cancer who experience difficulty swallowing. These patients often experience serious difficulties swallowing as a result of the location of the tumour or the radiotherapy used to treat it.

Multidisciplinary expertise across UHN will support the study: Quantitative Imaging for Personalized Cancer Medicine will provide medical imaging and radiation therapy solutions to enhance the reliability of study data; and Health Informatics Research will customize technology solutions to support the high-quality collection of patient-reported outcomes and clinical research data.

PRO-ACTIVE was selected through a highly competitive review process in which patients, caregivers and other stakeholders joined scientists to evaluate the proposals.



Building Capacity for Innovation

The Canada Foundation for Innovation awarded \$20.9 million to UHN for state-of-the-art research infrastructure. Through its Innovation Fund, two projects received large-scale awards. The first was the Princess Margaret Cancer Centre Precision Medicine Program (led by Dr. Brad Wouters), which was granted \$11.8 million—the second largest award in this competition—to develop new ways of profiling tumours. The second, CenteR for Advancing Neurotechnological Innovation to Application (CRANIA) (led by Dr. Milos Popovic), was awarded \$6.5 million to create new therapies for neurological diseases and conditions.

Through the John R. Evans Leaders Fund, UHN secured \$2.6 million for projects led by Dr. Bryan Coburn (personalized microbiology); Dr. Adam Gehring (immune therapy for viral hepatitis); Dr. David Jaffray (robotic radiobiology); Dr. Michael Laflamme (repair of injured hearts using stem cells); Dr. Tracy McGaha (tumour immunology); Dr. Philippe Monnier (retinal and neurodegenerative diseases); and by Dr. Mathieu Lupien (new treatments for difficult-to-treat cancers).



Advancing Cancer Immune Therapy

Two projects, led by UHN researchers Dr. Pamela Ohashi and Dr. Mathieu Lupien, were selected for funding by the Terry Fox Research Institute.

Dr. Ohashi will receive \$5.41 million to advance her investigations into the use of cancer immune therapy—a strategy that uses the body's immune system to kill cancer cells. A world-renowned pioneer in this field and the Co-Director of UHN's Tumour Immunotherapy Program, Dr. Ohashi will use the funds to develop and evaluate new immune therapies for high-grade serous ovarian cancer, the deadliest type of ovarian cancer.

Dr. Lupien will receive \$2.25 million towards his immune therapy research. His project will focus on advancing immune therapy for women with triplenegative breast cancer, a type of cancer that tends to have lower survival and higher recurrence rates.

These projects were two of six funded projects, representing approximately 30% of total funds awarded nationally.

Discovery

A selection of top research findings



Clearing the Way

Nanoparticles are microscopic particles that can be linked to anti-cancer drugs for delivery to tumours. While effective in experimental systems, nanoparticles often fail in patients because they become trapped in the liver and do not reach the tumour.

To identify the reason for this, a team led by Dr. Ian McGilvray and the University of Toronto's Dr. Warren Chan examined how nanoparticles interact with liver cells. They found that nanoparticles slow down upon entry into the liver from the blood stream—giving liver cells time to eliminate them from the body.

These results suggest that future strategies should consider ways to condition the liver to reduce nanoparticle removal. *Tsoi KM*, et al. Nat Mater. 2016 Nov;15(11):1212-1221.



The Magnificent 17

A research team led by Dr. Jean Wang has developed a genetic test that better predicts which leukemia patients will respond to standard therapies. The test's prediction is based on 17 genes found in leukemia stem cells, which are instrumental in disease initiation and recurrence.

The test was created to help those with a type of leukemia known as acute myeloid leukemia, which is notoriously difficult to treat: standard therapies fail in up to 60% of young adults and 85% of older adults with the disease.

By identifying which patients will not respond to standard therapies, the test could help avoid unnecessary treatments, and identify those who may benefit from more experimental or intensive treatment strategies. Plans are underway to evaluate the test in a clinical trial. Ng SW, et al. Nature. 2016 Dec 15;540(7633):433-437.



Stroke of Genius

This year, a first-of-its-kind app was launched to provide clinicians with best practice rehabilitation strategies for patients with arm impairments due to stroke.

The ViaTherapy app, developed through a global collaboration led by rehabilitation researchers Drs. Mark Bayley and Steven Wolf (Emory University), is the result of more than five years of research by a panel with expertise in physical and occupational therapy.

The app assists physicians in recalling established stroke therapies and in learning about new ones, making it easier for them to evolve their treatment plans based on how far along the patient is in their recovery.

www.viatherapy.org.



A Gut Reaction

A study led by Dr. Robert Inman showed that immune cells originating in the gut may promote disease in a form of arthritis known as ankylosing spondylitis (AS).

This type of arthritis is characterized by painful swelling in the back and neck joints that occurs when the immune system attacks the body's cells.

Dr. Inman discovered a type of immune cell that develops in the gut—known as a mucosal-associated invariant T cell—and that promotes harmful joint inflammation.

These findings strengthen the possibility that immune cells originating in the gut play a role in AS, while providing new molecular targets that could inform the development of new treatments. *Gracey E, et al. Ann Rheum Dis.* 2016 Dec;75(12):2124-2132.



Assisted Dying at UHN

A report describing UHN's implementation of an assisted dying program, led by Dr.

Madeline Li, was published in the New England Journal of Medicine.

Since February 2016, medical providers in Canada have been delivering medical assistance in dying (MAiD) to eligible patients. However, there is little information on the best way to implement MAiD in a hospital. UHN's report is intended to help address this knowledge gap.

Briefly, UHN's program consists of voluntary medical teams who assess eligibility, ensure informed consent and deliver the intervention. It also includes a committee that provides oversight, reports metrics and stewards data. During its first year of operation, the program provided MAiD to 19 patients. *Li M, et al. N Engl J Med. 2017 May* 25;376(21):2082-2088.



Protecting Brains

More than 216 million people worldwide suffer from malaria, a disease caused by parasite-infected mosquitos. If left untreated, it can progress to cerebral malaria, which can cause irreversible brain damage and death.

Based on the observation that people with cerebral malaria have low levels of the protein Ang-1, Dr. Kevin Kain used experimental models to gain a better understanding of the role of Ang-1 in the disease. He found that Ang-1 protects blood vessels in the brain during cerebral malaria, and that treatment with Ang-1 improved survival compared to treatment with conventional therapy. These exciting findings suggest that Ang-1-based therapies can be developed and tested to improve outcomes for this globally relevant disease. Higgins SI, et al. Sci Transl Med. 2016 Sep 28;8(358):358ra128.

Impact

How research at UHN is improving health care



Safety Device Inspired by Nature

NeuroShield has been referred to as an 'airbag for the brain'. It was launched by Bauer, a leading hockey equipment manufacturer, at a press conference attended by the company's spokesman and hockey legend Mark Messier.

The collar-like device sits around an athlete's neck and applies a slight pressure, increasing the volume of venous blood in the brain. The excess blood creates a 'cushion' between the skull and the delicate tissues of the brain, protecting the latter against the microscopic damage caused by blows to the head. The concept for the device was inspired by the woodpecker's physiology, which protects the bird's brain while drumming its beak against trees.

Dr. Joseph Fisher was one of the three clinicians who developed NeuroShield. The device was evaluated for safety in clinical trials involving high school soccer and football players, although device's ability to protect against concussions has not yet been validated. Q30 Innovations, a US-based research and development company, acquired the commercial rights for the device and partnered with Bauer to bring it to market.



A Superior Test for Sleep Apnea

An at-home sleep apnea test known as BresoDx is now available to Ontario patients for the first time as the result of a unique MaRS program.

The breakthrough device—invented by Drs. Hisham Alshaer, T Douglas Bradley and Geoff Fernie—is available at sleep clinics across the province. Ontario patients can use BresoDx to test for sleep apnea in the comfort of their homes rather than in a sleep laboratory. It is the first technology to complete the MaRS EXCITE program, an innovative initiative that accelerates the adoption of health technology in Ontario.

Sleep apnea affects around 10% of adults, yet fewer than 15% of North Americans who have the condition have been diagnosed. Left untreated, sleep apnea leads to chronic sleeplessness and an increased risk of developing more serious conditions such as stroke and heart failure.

By enabling the launch of BresoDx across the province, the Ministry of Health and Long-Term Care is paving the way for early diagnosis and treatment of sleep apnea.



Sights Set on Helping the World

MolecuLight i:X is a handheld device that uses fluorescence imaging to visualize bacteria in wounds. The device provides doctors with a quick readout of the status of wounds and infections—providing important health insights that are otherwise invisible to the naked eye.

The technology was developed at UHN by Dr. Ralph DaCosta and spurred the creation of the MolecuLight spin-off company. Now, it is poised for world-wide adoption: a distribution agreement has been signed between MolecuLight and UK-based Smith & Nephew that will put the technology into the hands of clinicians and patients around the world.


"MolecuLight i:X enhances clinicians' ability to choose the right therapy, at the right time for their patient," says Dr. Andy Weymann, Chief Medical Officer at Smith & Nephew. The device's ability to visualize wounds and infections will help guide wound management and treatment, contribute to the monitoring of hospital-acquired infections, and aid hospital-based programs that aim to minimize unnecessary use of antibiotics.

Inventor of the Year

DR. CHRISTOPHER PAIGE



Dr. Christopher Paige received
the 2016 award for his work in
immune-oncology. He developed
a therapeutic approach whereby a
patient's cancer cells are removed,
engineered to produce certain
chemical messengers and reintroduced to the patient, which
then stimulates immune cells to
have potent anti-cancer activity. A
clinical trial is now underway and
the technology was licensed by the
UHN company AvroBio Inc.



Putting Patients First

The Princess Margaret Cancer Foundation





The transformation, which started in May 2017, includes renovation of the Blood Collection Centre (artist's rendering, left) and a fully redesigned and renovated Murray Street entrance (artist's rendering, right)—both of which will improve the patient experience.

This year, The Princess Margaret (PM) Cancer Foundation launched its *Transformation Campaign*. With a goal of raising \$50 million in donations, the campaign supports a multi-phase project to transform the facilities at PM Cancer Centre—improving the patient experience from the moment they step through the doors.

Approximately one in six patients volunteers to participate in a clinical trial during their cancer journey. These patients collectively donate more than 26,000 blood samples each year toward finding new and improved ways of treating cancer. The efficient collection, management and storage of these precious samples are critical to bench-to-bedside research.

To this end, part of the *Transformation Project* will include a redesign of the *Blood Collection Centre*. It will undergo an expansion and reorganization to accommodate three more accessible collection stations, an expanded reception and waiting area and key functional upgrades.

The redesigned facility will enable blood samples to be analyzed in a more rapid and efficient manner, delivering robust information to scientists for discovering new ways to individualize cancer care. One such approach is the examination of circulating tumour DNA, which comprises genetic material that is released into the blood by certain tumours. By decoding the sequence of this genetic material, scientists can develop tests to monitor a patient's response to therapy or to predict the effectiveness of novel anti-cancer drugs.

"This project will facilitate clinical research, helping to ensure that our world-class team can meet the individual needs of every patient," explains Dr.

Mary Gospodarowicz, Medical Director of the PM Cancer Centre.

By providing a seamless integration of research throughout the cancer journey, this highly functional transformation will advance the institution's committment to patient-centered care. It will also accelerate research and innovation of new treatments and technologies that put patients' needs first.

A Night of Discovery

Toronto General & Western Hospital Foundation







(Left image) The Discovery Ball featured live music; (top right image, L-R) an on stage discussion between Krembil Director Dr. Don Weaver and science communicator Jay Ingram; (bottom right image) buttons for scientific attendees.

The first *Discovery Ball*—a fundraising initiative led by Toronto General & Western Hospital Foundation—took place on October 15, 2016. The goal of the event was to promote the Krembil Research Institute's research successes and raise money to support research into cures for diseases of the brain, spine, bones, joints and eyes.

A candid conversation between Krembil Director Dr. Donald Weaver and science communicator Jay Ingram was featured on the main stage. Researchers in attendance wore "ask me about my research" buttons, encouraging discussions on the valuable work happening at the Krembil and giving the philanthropists an opportunity to understand how important their contributions were to developing cures, while creating an air of collaboration and discovery.

The Discovery Ball was the brainchild of Stacey Krembil, who was also co-chair of the planning committee with Dr. Michael Baker, who hosted the event. The night was well attended, with nearly 400 distinguished guests, including philanthropists, UHN leadership and Krembil-affiliated researchers.

The event included a raffle for prizes such as a diamond rivière necklet and a live auction, hosted by broadcaster, award-winning writer and producer Husein Madhavji capped the event. The highest bidders won the opportunity to tour the labs of Dr. Weaver and Krembil Senior Scientist Dr. Mohit Kapoor, a prize that further underscored the discovery theme.

The event pairs people committed to advancing health care with Kremil researchers.

The event raised nearly \$1 million to support research at the Krembil. Because of its success, the Discovery Ball will continue as a staple of the Toronto General & Western Hospital Foundation's fundraising efforts, with the next event scheduled for October 2018.

Where Incredible Happens

Toronto Rehab Foundation









(Left and middle images) Dr. Milos Popovic (red tie) and his trainees demonstrating the capabilities of REL's specialized equipment; (right image, L-R) Maris Uffelmann and Dean Connor, donors who pledged \$1 million in support of REL.

At Toronto Rebilitation Institute (TRI), researchers work tirelessly to develop new therapies and products that restore function after illness or injury and enable independent living within the community.

In October 2015, the Toronto Rehab Foundation launched its *Where Incredible Happens* campaign, which aims to raise \$100 million to support TRI researchers, programs and facilities, which are instrumental in developing life-changing inventions. Inspired by TRI's work, Dean Connor, the President and CEO of Sun Life Financial and a Vice-Chair of UHN's Board of Trustees, agreed to lead the campaign.

Dean and his wife, Maris Uffelmann, demonstrated their personal commitment to the campaign through an incredible \$1 million gift to support TRI's Rehabilitation Engineering Lab (REL). REL is located at Toronto Rehab's Lyndhurst Centre, home of Canada's largest rehabilitation program devoted to spinal cord injuries.

"There are few moments in life when you have the power to significantly improve the lives of people around you," says Dean. "We are happy to be able to help."

REL is led by Dr. Milos Popovic, the TRI Chair in Spinal Cord Injury Research, and employs more than 40 researchers, trainees and staff. Dr. Popovic's research has yielded novel technologies—such as functional electrical stimulation therapy—that produce unparalleled levels of recovery in people affected by stroke or spinal cord injuries: they have improved patients' balance and restored their ability to walk, reach and grasp objects. His research is also making important advances in brain-machine interfaces, functional assessment tools, rehabilitation techniques and neuroprosthesis systems.

Dean and Maris's generous gift is enabling REL to undertake two high-risk, high-payoff projects. The funds are supporting trainees and staff examining the use of electrical stimulation to treat depression and of brain-machine interfaces to restore upperlimb function in stroke survivors.

Research Distinctions

Selected honours bestowed upon UHN researchers

Dr. Elizabeth Badley

2017 Distinguished Scholar Award, Association of Rheumatology Health Professionals

Dr. Philippe Bedard

2017 William E. Rawls Prize, Canadian Cancer Society

Dr. David Cescon

2017 Dr. Elizabeth Eisenhauer Early Drug Development Young Investigator Award, Canadian Cancer Trials Group

Dr. Vinod Chandran

2017 Young Investigator Award, Canadian Rheumatology Association

Dr. B Catharine Craven

2017 Award of Merit, Canadian Association of Physical Medicine & Rehabilitation

Dr. Marcelo Cypel

Tier 2 Canada Research Chair in Lung Transplantation (renewal)

Dr. Karen Davis

2017 Outstanding Pain Mentorship Award, Canadian Pain Society

Dr. Daniel De Carvalho

Tier 2 Canada Research Chair in Cancer Epigenetics and Epigenetic Therapy

Drs. Daniel De Carvalho and Mathieu Lupien

2017 Bernard and Francine Dorval Prize, Canadian Cancer Society

Dr. Eleftherios Diamandis

2017 Lifetime Achievement Award, Ontario Society of Clinical Chemists

Dr. John Dick

2017 Tobias Award Lecture, International Society for Stem Cell Research

2016 Gold Leaf Prize for Discovery, Canadian Institutes of Health Research

Tier 1 Canada Research Chair in Stem Cell Biology (renewal)

2017 Keio Medical Science Prize, Keio University

Dr. Michael Fehlings

2017 David Lostchuck Memorial Research Award, Canadian Spinal Research Organization

Dr. Eleanor Fish

2017 Leadership in Advocacy Award, Research Canada

Dr. Mary Gospodarowicz

2017 Wendy Lack Women of Action Scientific Award, Israel Cancer Research Fund

Dr. Housheng Hansen He

2017 New Investigator Award, The Terry Fox Research Institute

Dr. Mitsuhiko Ikura

Tier 1 Canada Research Chair in Cancer Structural Biology (renewal)

Dr. Jonathan Irish

President, American Head & Neck Society

Dr. Michael Jewett

2017 Exceptional Leadership in Patient Involvement in Cancer Research Award, Canadian Cancer Research Alliance

Dr. Anthony Lang

2017 MDS Pan-American Section Leadership Award, International Parkinson and Movement Disorder Society

Dr. Gary Levy

2017 Lifetime Achievement Award, Canadian Society of Transplantation

Dr. Andres Lozano

2017 Khwarizmi International Award, Iranian Research Organization for Science and Technology

2017 Bachmann-Strauss Prize for Excellence in Dystonia Research, Michael J. Fox Foundation for Parkinson's Research

Dr. Mary Pat McAndrews

2017 Excellence in Research Award, Canadian League Against Epilepsy

Dr. Brian O'Sullivan

2017 O. Harold Warwick Prize, Canadian Cancer Society

Dr. Amit Oza

GOC Presidential Medal, Society of Gynecologic Oncology of Canada

Dr. Christopher Paige

2017 Leadership in Advocacy Award, Research Canada

Dr. Kara Patterson

2017 Innovation and Advancement Award, Ontario Physiotherapy Association

Dr. Trevor Pugh

2017 New Investigator Award, The Terry Fox Research Institute

Dr. Milica Radisic

2017 Steacie Prize for Natural Sciences, E.W.R.Steacie Memorial FundTier 2 Canada Research Chair in FunctionalCardiovascular Tissue Engineering (renewal)

Dr. Gary Rodin

2017 Bernard Fox Memorial Award, International Psycho-Oncology Society

Dr. Frances Shepherd

2017 Addario Lectureship Award, Bonnie J.Addario Lung Cancer Foundation2017 Women for Oncology Award, European Society for Medical Oncology

Dr. Lillian Siu

Member, Board of Directors, American Association for Cancer Research

Dr. Charles Tator

Officer, Order of Canada (promotion from Member)

Dr. Ming-Sound Tsao

2016 Dr. Joseph Pater Excellence in Clinical Trials Research Award, Canadian Cancer Trials Group

Dr. Michael Tymianski

Member, Order of Canada

Dr. Murray Urowitz

2017 Distinguished Clinical Investigator Award, American College of Rheumatology

Dr. Sharon Walmsley

Member, Order of Canada

Dr. Minna Woo

Tier 2 Canada Research Chair in Signal Transduction in Diabetes Pathogenesis (renewal)

Dr. Bradly Wouters

Tier 1 Canada Research Chair in Hypoxia and the Tumour Microenvironment

Dr. Azadeh Yadollahi

Early Researcher Award, Ontario Ministry of Research, Innovation and Science

Dr. José Zariffa

Early Researcher Award, Ontario Ministry of Research, Innovation and Science

UHN Research Institutes

Krembil Research Institute

Princess Margaret Cancer Centre

Toronto General Hospital Research Institute

Techna Institute

Toronto Rehabilitation Institute

Krembil Research Institute

TOTAL RESEARCHERS	216	RESEARCH SPACE	154,001 sq. ft.
Total Appointed Researchers	92	EXTERNAL FUNDING	\$52,659,561
Senior Scientists	31		
Scientists	11	TOTAL TRAINEES	120
Affiliate Scientists	15	Fellows	48
Emeritus	2	Graduate Students	72
Clinician Investigators	33		
		TOTAL STAFF	276
Clinical Researchers	124		
		PUBLICATIONS	947

Research Council

Director and Chair, Krembil Research Institute Donald Weaver

Division Head, Fundamental Neurobiology Peter Carlen

Division Head, Healthcare & Outcomes Research Aileen Davis

Division Head, Brain Imaging & Behaviour - Systems Neuroscience Karen Davis

Division Head, Genetics & Development James Eubanks

Co-Director, Donald K. Johnson Eye Institute Valerie Wallace

Clinical Representative, Arthritis Program Robert Inman

Research Director, Arthritis Program Mohit Kapoor

Medical Director, Arthritis Program Nizar Mahomed

Chair, Trainee Affairs Committee Frances Skinner

Executive Director, Research Operations Lisa Alcia

Vice President and Site Lead, Toronto Western Hospital Janet Newton

Executive Vice President, Science and Research Bradly Wouters

Researchers

Brain, Imaging & Behaviour-Systems Neuroscience

Senior Scientists
Jonathan Brotchie
Robert Chen
Karen Davis
William Hutchison
Sidney Kennedy
Andres Lozano
Mary Pat McAndrews
David Mikulis
Antonio Strafella
Scientists
Jonathan Downar

Mojgan Hodaie Affiliate Scientists Mark Guttman Clement Hamani Walter Kucharczyk

Fundamental Neurobiology

Senior Scientists Peter Carlen Frances Skinner Shuzo Sugita Michael Tymianski Donald Weaver Scientists
Jérémie Lefebvre
Ivan Radovanovic
Taufik Valiante
Affiliate Scientists
Magdy Hassouna
Liang Zhang
Georg Zoidl

Genetics & Development

Emeritus Charles Tator Senior Scientists Cathy Barr James Eubanks
Michael Fehlings
Robert Inman
Mohit Kapoor
Lyanne Schlichter
Elise Stanley
Joan Wither
Scientists
Nigil Haroon
Lorraine Kalia
Suneil Kalia
Armand Keating
Affiliate Scientist
Sowmya Viswanathan

Healthcare & Outcomes Research

Emeritus
Murray Urowitz
Senior Scientists
Elizabeth Badley
Aileen Davis
Dafna Gladman
Nizar Mahomed
Scientist
Anthony Perruccio
Affiliate Scientists
Vinod Chandran
Paul Fortin
Monique Gignac
Rosemary Martino

Patient-based Clinical Research

Senior Scientist Anthony Lang

Donald K. Johnson Eye Institute

Senior Scientists
Philippe Monnier
Christopher Hudson
Valerie Wallace
Agnes Wong
Scientist
Jeremy Sivak
Affiliate Scientists
Moshe Eizenman
John Flanagan
Brenda Gallie
Esther González

Clinician Investigators

Dimitri Anastakis Danielle Andrade Heather Baltzer Mark Bernstein Anuj Bhatia Michael Brent Daniel Buchman Frances Chung Melanie Cohn Robert Devenyi Dean Elterman Alfonso Fasano Susan Fox Kenneth Fung Rajiv Gandhi Timothy Jackson

Efrem Mandelcorn Daniel Mandell Shane McInerney Roger McIntyre Renato Munhoz Laura Passalent Fayez Quereshy Y Raja Rampersaud David Rootman Cheryl Rosen Allan Slomovic David Tang-Wai M Carmela Tartaglia Zahi Touma Christian Veillette M Elizabeth Wilcox Mateusz Zurowski

Clinical Researchers

Ronit Agid Jamil Ahmad Peter Ashby Yaron Avitzur Brian Baker Paul Binhammer **Jeff Bloom** Arthur Bookman Sarah Brode Richard Brull Esther Bui Yvonne Buys Simon Carette Leanne Casaubon J David Cassidy Rodrigo Cavalcanti Ias Chahal Clara Chan Vincent Chan Kenneth Chapman Caroline Chessex Angela Cheung Ki Jinn Chin Maria Cino Michael Cusimano J Roderick Davey I Martin del Campo Sherif El-Defrawy W Mark Erwin Richard Farb Paul Fraser David Frost Alberto Goffi Eyal Golan Ewan Goligher Allan Gordon

Brent Graham

Barry Greenberg Raed Hawa Robert Iwanochko Sindhu Johnson Ron Keren Kvle Kirkham Stephen Kraft Timo Krings Debbie Kwan Jeffrey Kwong Robert Lam Wai-Ching Lam Johnny Lau Stephen Lewis Joel Lexchin Charles Lynde Angela Mailis-Gagnon Mark Mandelcorn Pirjo Manninen Katie Marchington Samuel Markowitz Patricia Marr Connie Marras Theodore Marras Eric Massicotte Steven McCabe Azadeh Moaveni Rakesh Mohankumar Ali Naraghi Ahtsham Niazi Ivv Oandasan Darrell Ogilvie-Harris Allan Okrainec Christian Pagnoux Daniel Panisko Christine Papoushek Sagar Parikh Philip Peng Vitor Pereira Anahi Perlas Aleksandra Pikula Atul Prabhu Sidney Radomski Sapna Rawal Shail Rawal Avlin Reid Rowena Ridout

Iennifer Robblee

Sandra Robinson

Jorge Sanchez-Guerrero

Arjun Sahgal

Paul Sandor

Monica Scalco

Hemant Shah

Michael Schwartz

David Salonen

Colin Shapiro Abdu Sharkawy Sanjay Siddha Frank Silver Martin Simons **Ieffrey Singh** Mandeep Singh Elizabeth Slow Sumeet Sodhi Neilesh Soneii Martin Steinbach[†] Barbara Stubbs Khalid Syed Peter Tai Susan Tarlo Maria Tassone Karel terBrugge Graham Trope Karen Tu Paul Tumber Andrea Velikovic Alexander Velumian Lakshmi Venkatraghavan Herbert von Schroeder Adam Weizman Richard Wennberg Robert Willinsky David K Wong David T Wong Jean Wong Eric Yu

Princess Margaret Cancer Centre

TOTAL RESEARCHERS	333	RESEARCH SPACE	416,488 sq. ft.
Appointed Researchers	82	EXTERNAL FUNDING	\$142,847,824
Senior Scientists	44		
Scientists	16	TOTAL TRAINEES	259
Affiliate Scientists	18	Fellows	124
Assistant Scientist	1	Graduate Students	135
Emeritus	3		
		TOTAL STAFF	857
Cancer Clinical Research			
Unit (CCRU) Members	251	PUBLICATIONS	1,192

Research Council on Oncology (RCO)

Director, PM Cancer Centre; Chair, RCO; Chair, Executive Committee (Interim) Rama Khokha Executive Committee Mitsuhiko Ikura, Rama Khokha, Mathieu Lupien, Pamela Ohashi, Gary Rodin, Aaron Schimmer, Vuk Stambolic, Ming-Sound Tsao, Brian Wilson, Gang Zheng

Chair, Appointments Committee Rama Khokha

Medical Director, Cancer Program Mary Gospodarowicz

Medical Director, Laboratory Medicine Program Runjan Chetty

Head, CCRU Amit Oza

Head, Medical Oncology and Hematology Amit Oza

Head, Radiation Medicine Fei-Fei Liu

Chief, Surgical Oncology Gelareh Zadeh

Executive Director, Research Operations Lisa Alcia

Senior Vice President and Site Lead, PM Cancer Centre Marnie Escaf

Executive Vice President, Science and Research Bradly Wouters

Researchers

Razqallah Hakem	Mathieu Lupien
David Hedley	Tak Mak
Naoto Hirano	Tracy McGaha
Doris Howell	Mark Minden
Mitsuhiko Ikura	Benjamin Neel
Norman Iscove	Pamela Ohashi
David Jaffray	Emil Pai
Jennifer Jones	Christopher Paige
Igor Jurisica	Linda Penn
Gordon Keller	Gilbert Privé
Rama Khokha	Brian Raught
Thomas Kislinger	Gary Rodin
Lothar Lilge	Robert Rottapel
Fei-Fei Liu	Aaron Schimmer
Geoffrey Liu	Vuk Stambolic
	David Hedley Naoto Hirano Doris Howell Mitsuhiko Ikura Norman Iscove David Jaffray Jennifer Jones Igor Jurisica Gordon Keller Rama Khokha Thomas Kislinger Lothar Lilge Fei-Fei Liu

Ming-Sound Tsao I Alex Vitkin Brian Wilson Bradly Wouters Gang Zheng Camilla Zimmermann

Scientists

Laurie Ailles
Scott Bratman
Steven Chan
Ralph DaCosta
Kim Edelstein
Benjamin Haibe-Kains
Housheng Hansen He
Michael Hoffman
Marianne Koritzinsky
Mohammad Mazhab-Jafari
Faiyaz Notta
Catherine O'Brien
Trevor Pugh
Rodger Tiedemann
Gelareh Zadeh

Assistant Scientist Christopher Marshall

Affiliate Scientists

Mark Brav Eric Chen Phedias Diamandis Ryan Dowling Mary Jane Esplen Anthony Joshua C Anne Koch Paul Kongkham Robert Kridel Beniamin Lok Michael Moran Michael Reedijk Leonardo Salmena Liran Shlush Suzanne Trudel Jean Wang Paul Waterhouse Wei X11

Cancer Clinical Research Unit (CCRU)

Ayman Al Habeeb Dominick Amato Eitan Amir Mostafa Atri Michael Baker Dwayne Barber David Barth Andrew Bayley Nathan Becker Philippe Bedard J Robert Beecroft Akbar Beiki-Ardakani Jennifer Bell

Robert Bell
Alejandro Berlin
Hal Berman
Marcus Bernardini
Lori Bernstein
Andrea Bezjak
Ivan Blasutig
Scott Boerner
Penelope Bradbury
Anthony Brade
William Brien
James Brierley

Robert Bristow
Dale Brown
Karina Bukhanov
Ronald Burkes
Marcus Butler
Jeannie Callum
Marco Carlone
Angela Cashell
Charles Catton
David Cescon
William Chapman
Tanya Chawla
Christine Chen
Terry Cheng
Douglas Chepeha

Carol Cheung
Charles Cho
John Cho
Young-Bin Cho
James Chow
Caroline Chung
Peter Chung
Tae Bong Chung
Tulin Cil

Runjan Chetty

Blaise Clarke
Sean Cleary
Tatiana Conrad
Tim Craig
Andrew Crean
Jennifer Croke
Michael Crump

Christine Cserti-Gazdewich

Bernard Cummings Gilda da Cunha Santos Norma D'Agostino Laura Dawson Jan Delabie Uday Deotare Neesha Dhani Robert Dinniwell Susan Done Iames Downar Daniel Drucker Alexandra Easson Elena Elimova Christine Elser Iaime Escallon Andrew Evans

Hannaneh Faghfoury Ronald Feld Peter Ferguson Sarah Ferguson Carina Feuz Antonio Finelli Neil Fleshner Warren Foltz Jeremy Freeman Anthony Fyles Lucia Gagliese Steven Gallinger William Geddie Fred Gentili Sandeep Ghai Sangeet Ghai Danny Ghazarian Ralph Gilbert Caitlin Gillan Meredith Giuliani Rebecca Gladdy David Goldstein Pamela Goodwin Chiara Gorrini

Chiara Gorrini Mary Gospodarowicz Rashmi Goswami Anand Govindarajan Paul Greig

Paul Greig Patrick Gullane Abha Gupta Vikas Gupta

Sara Hafezi-Bakhtiari Masoom Haider Sarah Hales Robert Hamilton Kathy Han

Anthony Hanbidge Breffni Hannon Aaron Hansen Robert Heaton Ioelle Helou Aaron Hendler David Hodgson Stefan Hofer David Hogg Shao Hui Huang Hyun-Jung Jang Raymond Jang Jeffrey Jaskolka Kartik Jhaveri Sarah Johnson Iohn Kachura Suzanne Kamel-Reid Zahra Kassam Ebru Kaya

Ebru Kaya
Harald Keller
Erin Kennedy
Korosh Khalili
Tim-Rasmus Kiehl
Dennis Kim
John Kim
Raymond Kim
Tae Kyoung Kim
Jennifer Knox
Hyang Mi Ko
Hatem Krema

Monika Krzyzanowska Vishal Kukreti Vathany Kulasingam Girish Kulkarni Supriya Kulkarni Kevin Kuo John Kuruvilla

Stéphane Laframboise

David Lam

Normand Laperriere Natasha Leighl Wey-Liang Leong Wilfred Levin Stéphanie Lheureux

Madeline Li
Winnie Li
Patricia Lindsay
Jeffrey Lipton
Christopher Lo
Helen Mackay
Ernie Mak
Lisa Martin
Warren Mason

Andrew Matthew
Catherine Maurice
Taymaa May
Dawn Maze
David McCready
Allison McGeer
Andrea McNiven
Maurene McQuestion

Hans Messner Ozgur Mete Fotios Michelis Barbara-Ann Millar Naomi Miller Michael Milosevic Nadeem Moghal Eric Monteiro Chantal Morel Lyndon Morley Douglas Moseley Carol-anne Moulton Anna Marie Mulligan Rumina Musani Alice Newman Rinat Nissim Martin O'Malley Anne O'Neill

Brian O'Sullivan Amit Oza Demetris Patsios Bayardo Perez-Ordonez

Andrew Pierre
Katherine Pisters
Anna Porwit
Anca Prica
Graeme Quest
Albiruni Razak
Donna Reece
Julia Ridley
Jolie Ringash
Paul Ritvo
Tara Rosewall

Lorne Rotstein Marjan Rouzbahman Anabel Scaranelo Heidi Schmidt Andre Schuh Jack Seki Stefano Serra Patricia Shaw Nadine Shehata Frances Shepherd David Shultz Hassan Sibai Lillian Siu
Joyce So
Anna Spreafico
Boraiah Sreeharsha
Srikala Sridhar
Alexander Sun
Carol Swallow
Joan Sweet
Tony Tadic
Ian Tannock
Anne Tierens
Ants Toi

Emina Torlakovic John Trachtenberg Richard Tsang Hubert Tsui

Theodorus van der Kwast

Michael Velec Auro Viswabandya Iohn Waldron Richard Ward Padraig Warde David Warr Ilan Weinreb Kirsten Wentlandt Lawrence White Ian Witterick Rebecca Wong Jay Wunder Karen Yee Erik Yeo Ivan Yeung Eugene Yu

Toni Zhong Alexandre Zlotta

Toronto General Hospital Research Institute

TOTAL RESEARCHERS	397	RESEARCH SPACE	171,800 sq. ft.
Appointed Researchers Senior Scientists	1 49 63	EXTERNAL FUNDING	\$72,491,550
Scientists	35	TOTAL TRAINEES	281
Affiliate Scientists	47	Fellows	104
Assistant Scientist	4	Graduate Students	177
Clinical Researchers	248	TOTAL STAFF	459
		PUBLICATIONS	1,454

Research Council

Director, TGHRI; Chair, TGHRI Research Council; Research Division Head (Acting),

Experimental Therapeutics Mansoor Husain

Research Division Head, Advanced Diagnostics Myron Cybulsky

Research Division Head, Support, Systems & Outcomes Murray Krahn

Clinical Program Head, Transplantation Atul Humar

Clinical Program Head, Peter Munk Cardiac Centre Barry Rubin

Physician-in-Chief; Clinical Program Head, Medical & Community Care Edward Cole

Surgeon-in-Chief; Clinical Program Head, Surgical & Critical Care Shaf Keshavjee

Chair, TGHRI Appointments Committee Thomas Waddell

Group Lead, Communities of Health Shabbir Alibhai

Group Lead, Cardiovascular Slava Epelman

Group Lead, Infection & Immunity Adam Gehring

Group Lead, Respiratory & Critical Care Mingyao Liu

Group Lead, Metabolism Minna Woo

Executive Director, Research Operations Lisa Alcia

Senior Vice President and Site Lead, Toronto General Hospital Scott McIntaggart

Executive Vice President, Science and Research Bradly Wouters

Researchers

Advanced	Eleanor Fish	Kumaraswamy	Eldad Zacksenhaus
Diagnostics	Jason Fish	Nanthakumar	Li Zhang
Senior Scientists	Joseph Fisher	York Pei	Scientists
Johane Allard	John Floras	Bruce Perkins	Moumita Barua
Peter Backx	Tony Lam	Barry Rubin	Filio (Phyllis) Billia
Daniel Cattran	Gary Lewis	James Scholey	David Cherney
Myron Cybulsky	Mingyao Liu	Katherine Siminovitch	Bryan Coburn
I George Fantus		Michael Wheeler	Shannon Dunn

Slava Epelman Anthony Gramolini Tianru Jin Ana Konvalinka Heather Reich Clinton Robbins Jonathan Rocheleau Paaladinesh

Thavendiranathan
Daniel Winer
Minna Woo
Affiliate Scientists
Donald Branch
Hong Chang
Peter Liu
Philip Millar
Anna Sawka
William Stansfield
Florence Wong
Assistant Scientist
Sonya MacParland

Experimental Therapeutics

Senior Scientists T Douglas Bradley Mark Cattral Marc de Perrot Niall Ferguson Herbert Gaisano Margaret Herridge Atul Humar Mansoor Husain Harry Janssen Kevin Kain Keyvan Karkouti Rupert Kaul David Kelvin Shaf Keshavjee Lakshmi Kotra Michael Laflamme Gary Levy Ren-Ke Li Nancy Olivieri Milica Radisic Vivek Rao Thomas Waddell Sharon Walmsley Richard Weisel Scientists Vijav Chauhan Chung-Wai Chow Marcelo Cypel

Satya Dash

Jordan Feld Adam Gehring Michael Gollob I Andrea McCart Ian McGilvrav M Cristina Nostro Nazia Selzner Lena Serghides Kazuhiro Yasufuku **Affiliate Scientists** Marisa Battistella Mamatha Bhat Gail Darling Gregory Downey Anand Ghanekar David Grant Raymond Hui Shahid Husain David Hwang Stephen Juvet Joel Katz Thomas Lindsay Tereza Martinu Cheri McGowan Raymond Reilly Sheila Riazi Heather Ross Michael Sefton Markus Selzner Morris Sherman Darrell Tan Terrence Yau **Assistant Scientists** Andrzej Chruscinski Sara Santana Nunes Vasconcelos

Support, Systems & Outcomes

Senior Scientists
Shabbir Alibhai
Anne Bassett
Claire Bombardier
Angela Cheung
Peter Cram
Abdallah Daar
Gunther Eysenbach
Alastair Flint
Allan Kaplan
Moira Kapral
Murray Krahn
Douglas Lee
Charmaine Lok
Robert Nolan

Gary Rodin Peter Singer Donna Stewart David Urbach Scientists Ana Carolina Alba Anna Gagliardi Bettina Hansen Sarbjit Vanita Jassal Ianet Raboud Valeria Rac Beate Sander **Affiliate Scientists** Thomas Forbes Suzanne Fredericks Alan Fung Sherry Grace Brian Hodges M Jane Irvine Adrienne Kovacs Jane MacIver Gail McVev Nicholas Mitsakakis Kathryn Nichol Karen Okrainec Marion Olmsted Jacob Pendergrast Rima Styra George Tomlinson Alice Wei D Blake Woodside **Assistant Scientist** Andy Wong

Clinical Researchers

Susan Abbey Peter Adamson Oyedele Adeyi Ganesh Annamalai Carmen Avila-Casado Mitesh Badiwala Mrinalini Balki Meyer Balter Joanne Bargman Carolina Barnett Alan Barolet W Scott Beattie Chaim Bell Lee Benson Matthew Binnie Robert Bleakney Andrea Boggild Isaac Bogoch Ari Breiner

Vera Bril James Brunton Jagdish Butany John Byrne Christopher Caldarone Douglas Cameron Carl Cardella Jose Carvalho Charles Chan Christopher Chan Cecilia Chaparro Anil Chopra Michael Christian Hance Clarke Paula Cleiman Edward Cole Evan Collins Iack Colman Patricia Colton Richard Cooper Adrian Crawley Kenneth Croitoru Sharon Cushing Robert Cusimano Kasia Czarnecka-Kujawa Patrick Darragh Kathleen Dattilo Tirone David Lorenzo Del Sorbo Diego Delgado Neal den Hollander Allan Detsky Michael Detsky Eleftherios Diamandis Gina Dimitropoulos George Djaiani Michael Domanski Eugene Downar Michelle Downes Andrei Drabovich James Duffin Vladimir Dzavik David Ellis Paul Ellis Eddy Fan Michael Farkouh Ludwik Fedorko Denice Feig Christopher Feindel Olavo Fernandes Sandra Fischer Jolene Fisher David Flamer

Steven Friedman

Toronto General Research Hospital Institute

Scott Fung Michael Gardam Susan George Peter Giacobbe Mihaela Ginj Shiphra Ginsburg Wayne Gold Roger Goldstein Avrum Gotlieb John Granton Gordon Greenberg Sandra Grgas Aliya Gulamhusein Andrew Ha Flavio Habal Kate Hanneman Paula Harvey Laura Hawryluck Carol Heck **Edward Hickey** Michelle Hladunewich Brian Hodges Eric Horlick Susy Hota Douglas Ing Nasir Jaffer Angela Jerath Rohan John Christine Jonas-Simpson Tuula Kalliomäki Sonja Kandel Hans Katzberg Rita Katznelson Edward Keystone Jay Keystone Yasmin Khan S Joseph Kim John Kingdom Caroline Kramer Kulamakan Kulasegaram Deepali Kumar Ayelet Kuper Bindee Kuriya Karim Ladha Megan Landes Stephen Lapinsky Patrick Lawler Christie Lee Lani Lieberman Leslie Lilly Yulia Lin Jessica Liu Louis Liu Alexander Logan

Kelly MacDonald Thomas MacMillan Christine Maheu Susanna Mak Jeffrey Man Cedric Manlhiot Katherine Marseu Azad Mashari Tony Mazzulli Stuart McCluskey Michael McDonald Micheal McInnis Robin McLeod Rory McQuillan Karen McRae Sangeeta Mehta Massimiliano Meineri Ravi Menezes Adam Millar Shikha Mittoo Ravi Mohan Andrew Morris Istvan Mucsi Patricia Murphy Gary Newton Elsie Nguyen Geoffrey Nguyen Marta Novak Erwin Oechslin Gerald O'Leary George Oreopoulos Mark Osten Mirek Otremba Maral Ouzounian Christopher Overgaard Mini Pakkal Blake Papsin Rulan Parekh John Parker Matteo Parotto Jesse Pasternak Keyur Patel Todd Penner David Pothier Susan Poutanen Lisa Puchalski Ritchie Harry Rakowski Dina Reiss Eberhard Renner Ravi Retnakaran

Robert Richardson

Michael Robinette

Gail Robinson

S Lucy Roche

Graham Roche-Nagle Patrik Rogalla Coleman Rotstein John Rutka Irving Salit Margaret Salmon Gonzalo Sapisochin Zion Sasson Jeffrey Schiff Leonard Schwartz **Joerg Schwock** Phillip Segal Rita Selby Mohammad Shafiee Maureen Shandling Shane Shapera Eran Shlomovitz Manohar Shroff Naveed Siddiqui Mark Silverberg Candice Silversides Lianne Singer Sunita Singh Samir Sinha Anna Skorzewska Peter Slinger Kenneth Sniderman Miranda So Sanjeev Sockalingam Christine Soong Danna Spears Coimbatore Srinivas A Hillary Steinhart Marshall Sussman Richard Swinson Adrienne Tan Kong Teng Tan John Thenganatt Seng Thipphavong Jussi Tikkanen Lianne Tile Kathryn Tinckam Sheldon Tobe Kathryn Trottier Wendy Tsang Alice Tseng Jacob Udell Amar Uxa Glen Van Arsdell Annette Vegas Allan Vescan Andrea Waddell Rachel Wald Paul Walfish

Marcin Wasowicz
Greg Wells
Cynthia Whitehead
Duminda Wijeysundera
David Wiljer
Stephen Wolman
Rene Wong
Anna Woo
Nicole Woods
Linda Wright
Robert Wu
Paul Yip
Bernard Zinman

Techna Institute

TOTAL RESEARCHERS	47	TOTAL TRAINEES	21
Core Leads	9	Fellows	8
Scientists	3	Graduate Students	13
Affiliated Faculty	35		
		TOTAL STAFF	106
RESEARCH SPACE	27,820 sq. ft.	Technology Development Team	45
		Other Staff	61
EXTERNAL FUNDING	\$11,586,816		
		PUBLICATIONS	346

Techna Leadership Team

Director, Techna Institute David Jaffray
Director, Clinical Processes Howard Abrams
Senior Director, Techna Innovation Luke
Brzozowski

Director, Knowledge Transfer Nicole Harnett Director, Research Faculty, Clinical Jonathan Irish Director, Research Faculty, Physical Sciences
J Paul Santerre

Director, Commercialization Mark Taylor Executive Vice President, Science and Research Bradly Wouters

Researchers

Design & Engineering for Health

Core Lead Joseph Cafazzo Affiliated Faculty Emily Seto Patricia Trbovich

Guided Therapeutics

Core Leads
Jonathan Irish
David Jaffray
Walter Kucharczyk
Scientists
Margarete Akens
Arash Zarrine-Afsar
Affiliated Faculty
Dionne Aleman
Timothy Chan
James Drake
Claire McCann
Cynthia Ménard
Alexandra Rink
Michael Sherar

Jean-Pierre Bissonnette Catherine Coolens John de Almeida Gabor Fichtinger Howard Ginsberg Justin Grant Mojgan Hodaie Andrew Hope Mohammad Islam Daniel Létourneau Andres Lozano Kieran Murphy Narinder Paul Thomas Purdie Dheeraj Rajan Teodor Stanescu Robert Weersink Bernd Wintersperger Kazuhiro Yasufuku

Informatics & Communications Technology

Core Leads Igor Jurisica Peter Rossos Affiliated Faculty Brenda Gallie Alejandro Jadad Michael Jewett Gordon Tait Christian Veillette

Nanotechnology & Radiochemistry

Core Leads Ur Metser Gang Zheng Affiliated Faculty John Valliant

Photonics

Core Lead Brian Wilson Scientist Ralph DaCosta Affiliated Faculty I Alex Vitkin

Toronto Rehabilitation Institute

TOTAL RESEARCHERS	118	RESEARCH SPACE	55,965 sq. ft.
Appointed Researchers Senior Scientists	111 23	EXTERNAL FUNDING	\$16,402,393
Scientists Affiliate Scientists	21 67	TOTAL TRAINEES Fellows Graduate Students	1 02 25 77
Clinical Researchers	7	TOTAL STAFF	104
		PUBLICATIONS	508

Research Advisory Council (RAC)

Director, TRI; Chair, RAC Geoff Fernie

Associate Academic Director of Research, TRI Susan Jaglal

Associate Scientific Director of Research, TRI Milos Popovic

Team Leaders Mark Bayley, Angela Colantonio, Tilak Dutta, Robin Green, Owen Lyons, Katherine McGilton, Alex Mihailidis, Paul Oh, B Catharine Craven, Catriona Steele, Yana Yunusova

Sub-Committee Chairs B Catharine Craven, Susan Jaglal, Katherine McGilton, Milos Popovic

Business Development & Organization Effectiveness Catharine Hancharek, Anthony Palma

Research Services & Operations Lois Ward

Senior Vice President and Site Lead, Toronto Rehab Susan Jewell

Executive Vice President, Science and Research Bradly Wouters

Researchers

Acquired Brain Injury & Society

Senior Scientists
Mark Bayley
Angela Colantonio
Scientist
Nora Cullen
Affiliate Scientists
Deirdre Dawson
Emily Nalder
Mary Stergiou-Kita

Artificial Intelligence & Robotics for Rehabilitation

Senior Scientist Alex Mihailidis Scientist Babak Taati **Affiliate Scientists**

Sonya Allin Jennifer Boger

Sven Dickinson

David Fleet

Deborah Hébert

Dana Kulić

Alan Mackworth

Goldie Neiat

Pascal Poupart

Rosemary Ricciardelli

Rosalie Wang

Brain Discovery & Recovery

Senior Scientist Robin Green Affiliate Scientists Asaf Gilboa Jennifer Steeves

Cardiorespiratory Fitness

Senior Scientists
David Alter
Sherry Grace
Scientists
Tracey Colella
Paul Oh
Affiliate Scientists
Jack Goodman
Krista Lanctôt
Walter Swardfager
Scott Thomas

Communication

Senior Scientists Elizabeth Rochon Yana Yunusova Scientist Frank Rudzicz **Affiliate Scientists** Melanie Baliko Boaz Ben-David Craig Chambers Tom Chau Petros Faloutsos Iulie Mendelson Aravind Namasivavam Frank Russo Gurjit Singh Pascal van Lieshout

Home, Community & Institutional Environments

Senior Scientists Geoff Fernie Andrea Furlan Scientists Jennifer Campos Tilak Dutta Bruce Haycock Behrang Keshavarz Alison Novak Christine Novak **Affiliate Scientists** Veronique Boscart Karen Gordon Dinesh Kumbhare Matthew Muller Hani Naguib Donald Philip Veronica Wadey

Mobility

Senior Scientists Mark Bayley Dina Brooks Brian Maki William McIlrov W Darlene Reid Scientists William Gage Avril Mansfield Kara Patterson **Affiliate Scientists** Alastair Flint Mary Fox Jesse Hoey Andrea Iaboni Elizabeth Inness Andrew Laing Sunita Mathur Laura Middleton George Mochizuki Stephen Perry **James Pratt** Luc Tremblay Karl Zabjek

Neural Engineering & Therapeutics

Senior Scientists

B Catharine Craven Milos Popovic Scientists César Márquez-Chin Kei Masani Kristin Musselman Jose Zariffa **Affiliate Scientists** Sandra Black Iulio Furlan Lora Giangregorio Sander Hitzig Pamela Houghton Ethne Nussbaum Linda Rapson Molly Verrier Timothy Welsh Paul Yoo

Optimization of the Rehab System

Senior Scientists Mark Bayley Cheryl Cott Andrea Furlan Susan Jaglal Pia Kontos Katherine McGilton I Gary Naglie Scientists Shabbir Alibhai Nora Cullen **Affiliate Scientists** G Ross Baker Veronique Boscart Jill Cameron Mary Fox Nancy Salbach Kathryn Sibley

Sleep Science

Senior Scientists T Douglas Bradley W Darlene Reid Scientists Hisham Alshaer Azadeh Yadollahi Affiliate Scientists Owen Lyons Clodagh Ryan

Swallowing Science

Senior Scientist Catriona Steele Affiliate Scientist Lisa Duizer

Clinical Researchers

Julia Alleyne Anthony Burns Ann Heesters Susan Marzolini Colleen McGillivray Denyse Richardson Gaétan Tardif

Research Committees

Biomedical Research Ethics Board: Panel A

Alan Barolet (Chair) Sharon Braganza Kim Cadario Derek Cathcart Robert Cusimano Seema David Erin Dobbelsteyn James Downar Nicole Feldman Scott Fung Peter Giacobbe Andrew Ha Matt Kim Iane Lui Connie Marras (Vice Chair) Heather Sampson Carl Virtanen Jean Wang Duminda Wijeysundera Noe Zamel

Biomedical Research Ethics Board: Panel B

Ian Arnold
Alan Barolet (Chair)
Ruth Anne Baron
David Barth
(Vice Chair)
Daniel Buchman
David Cherney
Natasha Danson
Nigil Haroon
Magdy Hassouna
Michael Hutcheon
Ali Naraghi
John Parker
Ron Seto
Morris Sherman

Samantha Sonshine Lorisa Stein Naomi Visanji Hannah Walters-Vida

Cancer Clinical Research Unit Executive Committee

James Brierley Pamela Degendorfer (Co-Chair) Penelope Bradbury Anthony Fyles Krystal Internicola (ex officio) Breffni Hannon **Jennifer Knox** Amit Oza (Chair) Michael Reedijk Patrik Rogalla Pam Savage Aaron Schimmer Susanna Sellmann Theo van der Kwast

Cancer Clinical Research Unit Management Committee

Rose Belcastro
Melanie Berger
Chantale Blattler
Cynthia Bocaya
(Interim)
Karen Chadwick
Bholy Chaudhary
Helen Chow (Interim)
Heather Cole
Pamela Degendorfer
(Chair)
Anna Dodd
Jeff Doi

Marcia Flynn-Post Jasmine Grant Julie Gundry Sisi Jia Tuula Kalliomäki Jennifer Li Karen Ng Gerard Paras Nishita Parekh Michele Petrovic (Interim) Jesus Piza-Rodriguez Tracey Powell Menaka Pulandiran Kendra Ross Maria Schlag Susanna Sellmann (Co-Chair) Vanessa Speers Marissa Tang Fong Ruth Turner Smitha Udagani (Interim) Celeste Yu

Cancer Registry and Data Access Committee

Niki Agelastos (Committee Secretariat) Penny Bradbury James Brierley (Chair) Carol Cheung Darlene Dale (Co-Chair) Alexandra Easson Calven Eggert David Goldstein Ioelle Helou John Kuruvilla Tony Panzarella Bayardo Perez-Ordonez

Clinical Studies Quality Committee

Lisa Alcia Charles Chan (Co-Chair) Jordan Feld John Floras Carole Garmaise John Granton Ann Heesters Iin Huh Deepali Kumar Paul MacPherson Paul Oh Amit Oza Patrik Rogalla Katie Roposa David Urbach Sharon Walmsley **Bradly Wouters** (Co-Chair)

Data Safety Monitoring Board

Mary Anne Chappell
Heather Cole (ex officio)
Kathy Han
Krystal Internicola
(ex officio)
Haiyan Jiang
Girish Kulkarni
John Kuruvilla
Srikala Sridhar (Chair)
Ruth Turner

Krembil Appointments Committee

Aileen Davis
Peter Carlen
Karen Davis
James Eubanks
Andres Lozano (Chair)
Valerie Wallace
Donald Weaver

Krembil Clinician Investigator Appointments Committee

Mary Pat McAndrews Y Raja Rampersaud Antonio Strafella Donald Weaver (Chair)

Krembil Space Committee

Aileen Davis Karen Davis James Eubanks (Chair) Ian McDermott Frank Vidic Valerie Wallace Donald Weaver Joan Wither

Krembil Trainee Affairs Committee

Anna Badner **Jason Charish** Jonathon Chio Leanne DaCosta Aidan Dineen Rachel Dragas Helal Endisha Nisah Ganeswaren Alexandre Guet-**McCreight** Peter Hung William Hutchison Amy Ma Mary Pat McAndrews Carley McPherson Samira Patel Kaitlyn Price Emma Reble Cricia Rinchon Anton Rogachov Kairavi Shah Frances Skinner (Chair) Alessandra Tuccitto

Uilki Tufa

Manoj Vasudeva Julie Wan Joan Wither Meital Yerushalmi

Oncology Research Ethics Board: Panel C

Eitan Amir (Vice Chair) Jennifer Bell Hal Berman Marcus Butler Michael Crump Stephanie DeLuca Robert Dinniwell Master Donald Iaime Escallon Ronald Feld Eli Fellman Anthony Fyles Robert Hamilton Aaron Hansen Jack Holland (Chair) Belling Leung Carmen Li Manjula Maganti Caroline McNamara Frank Michelis Rebecca Prince Nikolina Radulovich Albiruni Razak Katherine Renison Gordon Robinson Gregory St. Pierre Jenna Sykes Santhosh Thyagu Ruth Turner

PM Appointments Committee

Razqallah Hakem Richard Hill Norman Iscove David Jaffray Rama Khokha (Chair) Tak Mak Mark Minden Gilbert Privé Gary Rodin Robert Rottapel Vuk Stambolic

PM Equipment Committee

Laurie Ailles Mitsuhiko Ikura Rama Khokha Thomas Kislinger Trevor Pugh Robert Rottapel Malcolm Smith Ming-Sound Tsao Brian Wilson (Chair) Patrick Yau

PM Space Committee

Michael Hoffman Mitsuhiko Ikura Rama Khokha Pamela Ohashi (Chair) Gary Rodin Aaron Schimmer

Radionuclide Safety Committee

Shelley Belford

Jonathan Brotchie Gina Capone Perry Chong Mary Fountas Judy Gabrys (Co-Chair) Mihaela Gini David Green Norman Iscove Ian McDermott Ur Metser Jerry Plastino Deborah Scollard Frank Tourneur (Co-Chair) Li Zhang

Rehabilitation Medicine and Science Research Ethics Board: Panel D

Puja Ahluwalia Tania Artinian Jeffery Baine Carly Barbon Ahmed Bilal Jennifer Boger Anthony Burns Tracey Colella Carol Fancott Heather Flett Igor Gontcharov Ann Heesters (Chair) Shadi Katirai Pia Kontos Avril Mansfield César Márquez Chin Kei Masani Nadia Meli Sonia Minasian Ashwini Namasivayam Diane Nixon Stephanie Nixon Paul Oh (Vice Chair) Archna Patel Linda Penoyer Marta Pesin Karen Sasaki Catriona Steele Yervant Terzian Daniel Vena Rosalie Wang Rosalind Waxman Nykema Wright

Lesley Wylie

Research Biosafety Committee

Lorraine Kalia
Carly Rebelo
Jeanette MacLean
(ex officio)
Ian McDermott
(ex officio)
Badru Moloo (ex officio)
Gilbert Privé
John Shannon
(Acting Chair)

Research Risk and Audit Committee

Lisa Alcia (Chair) Chip Campbell Gabriella Fischer Tom Goldthorpe Tony Goncalves Alex Karabanow Sandra Karlovich Anthony Palma Amv Ma Paul MacPherson Carley McPherson Ian McDermott Peggy McGill Kathy McGilton Tracy McQuire Arjeta Meneri Badru Moloo Lisa Murphy Katie Roposa (Co-Chair) Evelina Rutkowski Gianfranco Scipione Anita Sengar John Shannon Mike Voth Lois Ward **Bradly Wouters**

TGHRI Appointments Committee

David Cherney
Angela Cheung
Myron Cybulsky
Murray Krahn
Anna Gagliardi
Margaret Herridge
Mansoor Husain
Robert Nolan
Brad Wouters
Jason Fish
Thomas Waddell
(Chair)
Minna Woo

TRI Central Patient & Subject Recruitment Committee

Mark Bayley
B Catharine Craven
(Chair)
Geoff Fernie
Susan Jaglal
Simon Jones

TRI International Scientific Advisory Committee

Martin Ferguson-Pell William Mann Anne Martin-Matthews (Chair) Alain Ptito Jerker Rönnberg John Steeves

TRI Junior Scientists' Support & Mentorship Committee

Tracey Colella Susan Jaglal (Chair) Avril Mansfield Lois Ward Azadeh Yadollahi

TRI Scientists' Productivity & Promotions Committee

Geoff Fernie Susan Jaglal Milos Popovic (Chair)

TRI Standard Operating Procedures Committee

Jennifer Campos
Geoff Fernie
(Co-Chair)
Catharine Hancharek
Susan Jaglal
Katherine McGilton
(Co-Chair)
Milos Popovic
Lois Ward

TRI Students' Support & Mentorship Committee

Susan Jaglal (Chair) Lois Ward Nisha Ganeswaren

TRI Team Leaders' Committee

Mark Bayley Angela Colantonio B Catharine Craven Tilak Dutta Geoff Fernie (Chair) Robin Green Catharine Hancharek (ex officio) Susan Jaglal Owen Lyons Katherine McGilton Alex Mihailidis Paul Oh Milos Popovic Catriona Steele Yana Yunusova

TRI Leadership Committee

Geoff Fernie Susan Jaglal Milos Popovic (Chair)

Patrick Yau

External Sponsors

Our partners provide key support for our research activities

Abbott AbbVie Acetylon Pharmaceuticals Acorda Therapeutics Actelion Pharmaceuticals ActiveO Acumyn Adamas Pharmaceuticals Adaptimmune Aeglea Biotherapeutics Aerie Pharmaceuticals AGA Medical Agensys AGE-WELL Agios Pharmaceuticals Alcon Canada Alexion Pharmaceuticals Alfred Health Alion Pharmaceuticals Allergan AllerGen Alnylam Pharmaceuticals Alpha Cancer Technologies Alzheimer Society of Canada Alzheimer's Association American Academy of Otolaryngology American Association for Cancer Research American Association for Thoracic Surgery American Association of Neurological Surgeons American College of Radiology Imaging Network American College of Rheumatology American Society of Hematology American Society of

Nephrology American Society of

Neuroradiology

American Society of Transplant Surgeons American Society of Transplantation American Thoracic Society Amgen Anesthesia Patient Safety Foundation **AOSpine** apceth Biopharma APOCARE Pharma Arbor Research Collaborative for Health Arbutus Biopharma Arthritis Research Foundation Associated Medical Services Association of University Radiologists Astellas Pharma Astex Pharmaceuticals AstraZeneca Avanir Pharmaceutical Barbara Ann Karmanos Cancer Institute Bard Canada Bavarian Nordic Baxter Bayer Beckman Coulter Benvenue Medical Beth Israel Deaconess Medical Bill & Melinda Gates Foundation BioCanRx Biocompatibles UK Biogen Biosensors International Boehringer Ingelheim Boston Biomedical Boston Children's Hospital Boston Medical Center

Boston Scientific

Brain & Behavior Research Foundation Brain Canada **BresoTEC** Bristol-Myers Squibb British Columbia Cancer Agency Canada Foundation for Innovation Canada Health Infoway Canada Research Chairs Canadian Agency for Drugs and Technologies in Health Canadian Allergy, Asthma and Immunology Foundation Canadian Anesthesiologists' Canadian Arthritis Network Canadian Association for the Study of the Liver Canadian Association of Psychosocial Oncology Canadian Association of Radiation Oncology Canadian Blood and Marrow Transplant Group Canadian Blood Services Canadian Breast Cancer Foundation Canadian Cancer Society Research Institute Canadian Diabetes Association Canadian Foundation for AIDS Research Canadian Frailty Network Canadian Heart Research Centre Canadian Hematology Society Canadian Institutes of Health Research Canadian Liver Foundation Canadian National Transplant Research Program Canadian Occupational Therapy Foundation

External Sponsors

Canadian Partnership Against CReATe Cord Blood & Peristem Hamilton Health Sciences Cell Bank Hauptman-Woodward Medical Cancer Research Institute Canadian Partnership for Stroke CSL Behring CTI BioPharma Health Technology Exchange Recovery Canadian Patient Safety Institute Cystic Fibrosis Canada Heart and Stroke Foundation of Canadian Psychological Daiichi Sankvo Canada Association Dartmouth College Heart and Stroke Foundation of Canadian Pulmonary Fibrosis Department of National Defence Ontario DLVR Therapeutics Foundation Hemostemix Henry Ford Health System Canadian Radiation Oncology **DNAtrix** Hôpital Maisonneuve-Rosemont Foundation Duke University Canadian Rheumatology Dystonia Medical Research Horizon Pharma Association Foundation Hospira Canadian Society of Hospital Edwards Lifesciences Hybridyne Imaging Elekta Technologies Pharmacists Icahn School of Medicine at Canadian Urological Association Eli Lilly Canada Cancer Care Ontario **EMD** Group Mount Sinai **Emory University** Cancer Research Institute Imago BioSciences Cancer Research Society Epilepsy Canada Immune Diagnostics & Research CannScience Innovations Epizyme ImmunoCellular Therapeutics Carestream Health Essilor **INC** Research Caris Life Sciences European Organisation for **Inception Sciences** CASI Pharmaceuticals Research and Treatment of **INSIGHTEC** Cedars-Sinai Medical Center Cancer Insmed Celgene Institut de recherche Robert-**Exact Imaging** Celsion Exelixis Sauvé en santé et en securité Centre for Addiction and Mental FedDev Ontario du travail Health Ferring Pharmaceuticals Institut universitaire de Centre for Commercialization of Fluidigm cardiologie et de pneumologie Regenerative Medicine Foundation Fighting Blindness de Québec Institute for Clinical Evaluative Centre hospitalier de Fred Hutchinson Cancer l'Université de Montréal Research Center Sciences Cervical Spine Research Society Fresenius Kabi Intercept Pharmaceuticals InterMune Children's Hospital of Eastern Friends of FACES International Human Frontier Ontario GBS/CIDP Foundation Children's Hospital of International Science Program Philadelphia GE Canada International Parkinson and Movement Disorders Society Chimerix Genentech CIHR Canadian HIV Trials International Rett Syndrome Genome Canada Network Genzyme Foundation George Institute for Global Cincinnati Children's Hospital International Society for Heart Medical Center Health & Lung Transplantation Cleave Biosciences Gilead Sciences International Society for Clinique La Prairie Glaucoma Research Society of Peritoneal Dialysis Colon Cancer Canada Interrad Medical Canada InVivo Therapeutics Columbia University GlaxoSmithKline Concordia Pharmaceuticals Global Affairs Canada **IQVIA** iRT Systems Conkwest Grand Challenges Canada Conquer Paralysis Now Israel Cancer Research Fund Grifols Cook Group Hackensack University Medical J.P. Bickell Foundation Craig H. Neilsen Foundation Center Jaeb Center for Health Research

Janssen Microbot Medical Ontario HIV Treatment Jewish General Hospital Ministry of Education Network Ontario Institute for Cancer Johns Hopkins University Ministry of Health and Long-Johnson & Johnson Term Care Research ISS Medical Research Ministry of Labour Ontario Institute for Juvenile Diabetes Research Ministry of Research, Regenerative Medicine Innovation and Science Ontario Lung Association Foundation Karyopharm Therapeutics Ontario Mental Health Mitacs Kiadis Pharma Foundation MolecuLight Ontario Neurotrauma Kidney Cancer Canada Morton Cure Paralysis Fund Kidney Foundation of Canada Mount Sinai Hospital Foundation Krembil Foundation Multiple Myeloma Research Ontario Stroke Network Foundation Kyowa Hakko Kirin Ontario Telemedicine Network Lawson Health Research Multiple Sclerosis Society of Ontario Thoracic Society Institute Canada Onyx Pharmaceuticals Leidos Biomedical Research Muscular Dystrophy Canada Ophthotech Otsuka Canada Pharmaceutical Leukemia and Lymphoma Myeloma Canada National Institutes of Health Ottawa Hospital Research Society Leukemia and Lymphoma National Multiple Sclerosis Institute Society of Canada Oxford Immunotec Society Leukemia Research Foundation National Research Council Panacea Global of Canada Natural Sciences and Pancreatic Cancer Canada Li Ka Shing Foundation Engineering Research Council Paralyzed Veterans of America LifeLabs of Canada Education Foundation Llewellyn Market Research Nestec **PAREXEL** London Health Sciences Centre Netherlands Cancer Institute Parkinson Canada Lundbeck Canada Networks of Centres of Parkinson's UK Lung Biotechnology Excellence Partners HealthCare Lupus Foundation of America NeuroDevNet Perimeter Medical Imaging Lupus Ontario New England Research Petro-Canada Lubricants Lupus Research Alliance Institutes Pfizer Pharmaceutical Product Lutonix New York University Mallinckrodt Pharmaceuticals Northern Biologics Development March of Dimes Northwestern University PharmaNet MaRS Innovation Notable Labs **Philips** Massachusetts General Hospital Nova Scotia Health Authority Phonak Matrizyme Pharma NOVADAQ Technologies Photopharmica Mayo Clinic **Novartis** Physicians' Services McGill University Novo Nordisk Incorporated Foundation NPS Pharmaceuticals McGuire Research Institute Physiotherapy Foundation of NRG Oncology McMaster University Canada Medical Council of Canada **NSABP** Foundation Pierre Fabre Medical Decision Modeling Nucleix PKD Foundation MedImmune Octapharma Polynoma Medivir Olympus Population Health Research Medtronic Onconova Therapeutics Institute Merck & Co. Onkocellular PRA Health Sciences Merrimack Pharmaceuticals Ontario Brain Institute Progenics Pharmaceuticals Ontario Centres of Excellence Merz Pharma Promedior Mesothelioma Applied Research Prometic Life Sciences Ontario Clinical Oncology

Group

Foundation

Promobilia Foundation

Prostate Cancer Canada Protagen ProteoMediX Proteon Therapeutics Prothena Providence Health Care Public Health Agency of Canada PuraPharm Queen's University Radiological Society of North America Raysearch Laboratories Regulus Therapeutics Revalesio Rick Hansen Foundation Rick Hansen Institute Roche Royal College of Physicians and Surgeons of Canada Saint Elizabeth Health Care Samuel Waxman Cancer Research Foundation Sandra Rotman Centre Sanofi Sarcoma Cancer Foundation of Canada Savoy Foundation Schering-Plough Seattle Children's Hospital Seguana Medical Shionogi Shire SickKids Siemens Sigma Theta Tau International Simon Fraser University Smiths Medical Society for Vascular Surgery Society of American Gastrointestinal and Endoscopic Surgeons Society of Anesthesia and Sleep Medicine Society of Uroradiology Southlake Regional Health Centre SpectraCure Spencer Foundation Spring Bank Pharmaceuticals

St. Joseph's Healthcare Hamilton

St. Mary's Research Centre

St. Jude Medical

St. Michael's Hospital Stanley Medical Research Institute State University of New York Stemline Therapeutics Stryker Sunnybrook Health Sciences Centre Sunovion Susan G. Komen Takara Bio Takeda Oncology TauRx Therapeutics TD Bank Group Ted Rogers Centre for Heart Research Terry Fox Research Institute Terumo Tesaro Thalassemia Foundation of Canada The Arthritis Society The Arthritis Society The MAYDAY Fund The Michael J. Fox Foundation for Parkinson's Research The Parkinson's Foundation The Plastic Surgery Foundation The Princess Margaret Cancer Foundation The Vitamin D Society The W. Garfield Weston Foundation Theralase Therapure Biopharma Thoratec Thornhill Medical Thrasos Innovation Threshold Pharmaceuticals Thrombosis Research Institute Tocagen Tokai Pharmaceuticals Tornado Spectral Systems Toronto Central Local Health Integration Network Toronto Dementia Research Alliance

Toronto General & Western

Toronto Rehab Foundation

Hospital Foundation


Toshiba Medical Systems

Trillium Therapeutics

Triphase Accelerator Corporation **UCB** United States Department of Defense University Hospital Tuebingen University of Alberta University of British Columbia University of Calgary University of California, Los Angeles University of California, San Diego University of California, San Francisco University of Chicago University of Colorado University of Florida University of Iowa University of Louisville University of Manitoba University of Maryland University of Medicine and Dentistry of New Jersey University of Miami University of Michigan University of Ottawa University of Pennsylvania University of Regina University of Rochester University of Saskatchewan University of Texas University of Toronto University of Virginia University of Washington University of Waterloo University of Western Ontario University of Zurich Urology Association of Portugal Vancouver Coastal Health Research Institute Veran Medical Technologies Vernacare Canada Vertex Pharmaceuticals Virginia Commonwealth University Wake Forest University Wings for Life Women's College Hospital

Financials

Research funding by source



TOTAL FUNDING \$386,192,252

Financial data provided by UHN Research Financial Services. The above figures represent funding revenues (by source) received to support direct and indirect research for the fiscal year ending March 31, 2017. The 'Government of Ontario' funding category represents contributions from provincial government programs, including the Ministry of Health and Long-Term Care, and the Ministry of Research, Innovation and Science (excluding the Ontario Research Fund Research Infrastructure Fund). Funding agencies/organizations that contributed \$3,500,000 or more are indicated.

*The Foundations donate to UHN for purposes in addition to supporting research. As per UHN's audited financial statements for the fiscal year ended March 31, 2017, grants and donations for research and other purposes provided by UHN foundations were: \$102,460,000 for The Princess Margaret Cancer Foundation; \$5,683,000 for the Toronto Rehab Foundation; and \$76,777,000 for the Toronto General & Western Hospital Foundation.

International Research Advisory Board

Samuel Weiss, PhD (Chair)

Professor, Departments of Cell Biology & Anatomy and Physiology & Pharmacology, University of Calgary; Inaugural Director of the Hotchkiss Brain Institute

Philip E Branton, OC, PhD, FRSC

Gilman Cheney Professor, Departments of Biochemistry and Oncology and the Goodman Cancer Centre, McGill University

Thomas Rockwell Mackie, PhD

Professor Emeritus, Medical Physics and Human Oncology, University of Wisconsin; Director, Medical Devices Focus Area, Morgridge Institute for Research

Lynne Warner Stevenson, MD

Director, Cardiomyopathy and Heart Failure Program, Brigham and Women's Hospital; Professor, Harvard Medical School

John E Wennberg, MD, MPH

Active Professor Emeritus of Community & Family Medicine, Peggy Y Thomson Professor Emeritus in Evaluative Clinical Sciences and Director Emeritus and Founder, The Dartmouth Institute for Health Policy & Clinical Practice

Research Committee Board of Trustees

Independent Trustees (Voting)

Lawrence Pentland (Chair), Barbara Stymiest, Trevor Young

Ex-officio Trustees (Voting)

Charlie Chan (Interim CEO), Joy Richards

Others (Voting)

Sean Boyd, Tom Ehrlich, Mark Krembil, John O'Grady

Ex-officio Non-Trustees (Non-voting)

Larry Baldachin, Darlene Dasent, John Granton, Bradly Wouters

Disclaimers

Publications, Personnel, Research Committees: Publication data provided by UHN Research Program Planning & Analysis. Leadership data provided by UHN institute Business Managers. Data accurate as of September 1, 2017. Some figures may be rounded and/or may include data not represented in institute data. Publications jointly authored by investigators at multiple UHN institutes are counted only once in the UHN total. Researchers with more than one affiliation within an institute, or between institutes, are only included once in the total count. Metrics for each institute were calculated by considering data on all Researchers, which include CCRU or Clinical Researchers as applicable. Please note that Clinical Researchers and CCRU investigators are not formally appointed at the research institutes and are therefore not subject to the research institutes' scientific and performance reviews. Clinical Researchers are defined as UHN staff who are listed as corresponding or principal author on at least one publication in the 2016 calendar year and/or held research funding over the 2016/17 fiscal year. †Dr. Martin Steinbach (p. 30) passed away on June 24, 2017.

Trainees: Institute trainee counts are accurate as of August 1, 2017 and were provided by UHN's Office of Research Trainees.

Counts reflect trainees supervised by researchers with a primary UHN research appointment and who spent more than 50% of their time at UHN.

Space: Data provided by UHN Research Facilities Planning & Safety and based on space audited by September 1, 2017 across UHN sites. Core facilities and Research Solutions and Services spaces are not included in institute space totals. Production Credits: This report is published by the Office of the Executive Vice President, Science and Research, UHN. Graphic design, writing and production by UHN's Strategic Research Initiatives Development Team (StRIDe). Institute Financials: The 'External Funding' value in each snapshot represents total research project funding received by investigators that are primarily affiliated with each specific institute in the 2016/17 fiscal year.



Innovation fuels our drive to make health care better, faster and stronger.

To learn more visit UHNresearch.ca





University Health Network Research Report 2017 | Office of the Executive Vice President, Science and Research. 200 Elizabeth Street, R. Fraser Elliott, 1-S-407, Toronto, Ontario, Canada

